Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

multidrug resistant infections

- PMLiVE

AstraZeneca picks location for global HQ and research base

Decides on the Cambridge Biomedical Campus in UK

- PMLiVE

AstraZeneca and NGM form diabetes/ obesity partnership

Will use MedImmune arm to develop treatments that target gastrointestinal hormones

- PMLiVE

AstraZeneca boosts R&D prospects with Pearl acquisition

Deal to acquire respiratory firm could be worth up to $1.15bn

- PMLiVE

FDA gives priority review status to BMS/ AZ’s metreleptin

Former obesity prospect has potential in the rare disease lipodystrophy

EU flag

Nine pharma firms face EU fines over pay-for-delay deals

Lundbeck could be the hardest hit with a maximum penalty of €240m

- PMLiVE

AstraZeneca drops arthritis candidate fostamatinib

Hands rights back to Rigel after late-stage trial disappointment

EU flag

EU Parliament panel backs updated clinical trials regulations

But pharma industry concerned about measures to increase transparency

National Institute for Health and Care Excellence NICE logo

NICE reverses negative guidance for Forxiga in diabetes

Final draft guidance backs the use of BMS/AstraZeneca’s SGLT-2 inhibitor in certain patients

- PMLiVE

Allergan veteran joins Kala as head of business development

Charles McDermott has experience in ophthalmology

- PMLiVE

Gilead launches combination HIV pill in UK and Germany

Stribild is approved in EU as once-daily single tablet

- PMLiVE

AstraZeneca offers $443m to buy Omthera

Adds to list of deals to boost flagging pipeline

- PMLiVE

Redx Pharma to open research centre at AstraZeneca’s Alderley Park site

Will focus on hard-to-treat infections

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links